PAVmed (PAVM) majority-owned subsidiary Lucid Diagnostics to spin-off into separate public company

Go back to PAVmed (PAVM) majority-owned subsidiary Lucid Diagnostics to spin-off into separate public company

PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results

February 22, 2021 8:18 AM EST

Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company

Lucid Diagnostics to launch major new multi-channel commercialization initiative for its EsoGuard Esophageal DNA Test

Conference call to be held today at 8:30 AM EST

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Lucid) and Solys Diagnostics Inc. (Solys), discussed preliminary financial results for the... More